Basics Krystal Biotech, Inc. Krystal Biotech Inc is a biopharmaceutical company. It uses gene therapy treatments for patients suffering from rare debilitating disorders. IPO Date: September 20, 2017 Sector: Healthcare Industry: Biotech Market Cap: $3.61B Activated in VL: True Average Daily Range Avg Daily Range: $1.79 | 2.66% Avg Daily Range (30 D): $2.76 | 1.88% Avg Daily Range (90 D): $3.53 | 2.19% Institutional Daily Volume Avg Daily Volume: .15M Avg Daily Volume (30 D): .29M Avg Daily Volume (90 D): .23M Trade Size Avg Trade Size (Sh.): 45 Avg Trade Size (Sh.) (30 D): 32 Avg Trade Size (Sh.) (90 D): 30 Institutional Trades Total Inst.Trades: 1,933 Avg Inst. Trade: $3.71M Avg Inst. Trade (30 D): $5.44M Avg Inst. Trade (90 D): $6.05M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $4.67M Avg Closing Trade (30 D): $7.01M Avg Closing Trade (90 D): $7.64M Avg Closing Volume: 40.36K         News Apr 28, 2025 @ 11:00 AM Krystal Biotech Announces European Commission Appr... Source: N/A Feb 19, 2025 @ 12:00 PM Krystal Biotech Announces Fourth Quarter and Full ... Source: Krystal Biotech, Inc. Jan 14, 2025 @ 1:00 PM Jeune Aesthetics Appoints Nishant Saxena as Chief ... Source: N/A Dec 19, 2024 @ 6:00 PM Comprehensive Market Analysis of Latest Published ... Source: Delveinsight Dec 18, 2024 @ 1:00 PM Krystal Biotech Announces Early Evidence of Monoth... Source: Krystal Biotech, Inc. Financials   TTM Q1 2025 Q3 2024 Basic EPS $1.24 $.95 Diluted EPS $1.2 $.91 Revenue $ $ 88.18M $ 83.84M Gross Profit $ $ $ Net Income / Loss $ $ 35.73M $ 27.18M Operating Income / Loss $ $ 36.18M $ 22.43M Cost of Revenue $ $ $ Net Cash Flow $ $ -36.1M $ 28.18M PE Ratio